Skip to main content

Artemis Funds (Lux) – SmartGARP Global Emerging Markets Equity update

The managers report on the fund over the quarter to 31 March 2024 and the outlook.

Source for all information: Artemis as at 31 March 2024, unless otherwise stated.

  • The fund returned 5.4% in US dollar terms, ahead of its benchmark the MSCI Emerging Markets index, which rose 2.4%
  • The fund's performance is in the top quartile vs IA GEM sector for one, three, five years and since inception
  • Emerging market stocks remain cheap and unloved, with abundant growth and income opportunities.
  • Value bias in the fund remains substantial, 41% discount to MSCI EM…
  • …with favourable quality and growth characteristics compared to the market.

Outperformance against a rising market

Emerging market stocks rose during the quarter, albeit lagging developed market stocks. Optimism around easing of monetary policy and encouraging economic data from around the world were supportive tailwinds for stocks. With diminishing signs of recessionary concerns, particularly in the US, risk appetite seems to have improved.

Technology and cyclical areas of the market led, as traditional defensives such as healthcare and consumer staples lagged. 'Value' stocks (those that trade on below-average valuations) were not able to keep pace with the market, although they did deliver positive returns in the quarter.

The fund outperformed, despite our significant bias towards value stocks. Improved sentiment is supportive to emerging markets, given the pessimism reflected in investor positioning.

Attribution – favourable tailwinds for our holdings

A diverse group of companies contributed to performance in the quarter, reflecting several positive tailwinds developing across our holdings. Top contributors in the first quarter were Indus Towers (telecoms), CNOOC (energy), JB Financial and PKO (banks) and Lao Feng Xiang (jewellery). AI-themed stocks in Taiwan also performed well, our holdings in Wiwynn and Ennoconn featured among top contributors. On the negative side, China Medical System shares fell following weaker guidance around revenues and earnings. Elsewhere, softer commodity prices created headwinds to our positions in the sector, with Kumba Iron and Gerdau amongst detractors. Despite the setbacks, the fund delivered strong outperformance in the quarter.

Key financial metrics

  12m forward P/E ROE Dividend yield
Fund 7.3x 15.0% 5.4%
Benchmark 12.2x 13.8% 2.9%
Relative -41% 1.2% 83%
Source: Artemis, Bloomberg, MSCI as at 31 March 2024. ROE is a blend of 3-year trailing and 2-year forward

Activity – adding to cyclicals in Asia

Signs of a bottoming in semiconductors and the tech hardware cycle encouraged us to reduce our underweight exposure to the sector somewhat.

Additions – improving fundamental trends

  • Semiconductors and electronic components – Hynix, Hon Hai and TSMC
  • Cyclicals – Star Bulk Carriers, Evergreen Marine and Weichai Power

Reductions - deteriorating fundamentals

  • Tech – Novatek, Lenovo, Foxconn
  • Banks – Tisco and Absa Group
  • Weak Q4 results – Gerdau, Ping An and Hello Group

The result of these changes is that the fund continues to offer an attractive combination of extremely low valuations and good growth prospects. We remain overweight China, Brazil and Korea and underweight India, Taiwan and Saudi Arabia. At the sector level, financials, consumer discretionary and industrials feature as the largest overweights. Materials, technology and consumer staples the largest underweights.

We remain positioned for a rotation into value stocks

The fund continues to offer an attractive combination of extremely low valuations and attractive growth prospects. The forward price/book ratio of the fund is 1 and it offers a forward P/E of 7.3 vs 12.2 for the index (a 41% discount). We think our discipline around valuations is likely to be a rewarding strategy as we progress through 2024 and for the years ahead. Typically, significant exposure to value stocks coincides with distressed balance sheets and volatile earnings. This doesn’t appear to be the case today: the fund offers favourable quality and growth characteristics. For instance, our net debt/EBITDA is significantly lower than the market and our free cash flow yield is also much higher than the market. We can achieve these compelling financial characteristics because of some behavioural biases that have caused over valuations in some parts of the market, leaving others under appreciated.

Pessimism well reflected in prices – cyclical upturn presents opportunity

For much of 2023, Chinese equity markets suffered from weaker sentiment. The Chinese economic recovery has so far been underwhelming. On the positive side, potential for stimulus measures and reasonable levels of interest rates offer support. Chinese stocks have struggled for over a decade and their share prices are well reflective of the risks highlighted. Positive catalysts such as reforms and growth initiatives have the potential to surprise investors. We have seen signs of stabilisation and believe the risk reward in China remains highly favourable

Shiller P/E by region

Bar graph showing Shiller PE by region

Source: Bloomberg as at 31 March 2024. Shiller P/E is the long-term price earnings ratio computed by dividing price by 10 year average real earnings per share. Real earnings per share is computed by adjusting the EPS ratio for the country’s consumer price index (CPI).

More broadly, emerging market stocks are trading on multi-decade valuation lows against developed markets across a range of metrics. Emerging market economies are ahead of the cycle and have started easing. More flexibility around monetary and fiscal policies is causing diverging paths with the west and supporting economic growth prospects ahead.

Our focus on fundamentals continues

We continue to believe that a focus on companies’ fundamentals, such as earnings and cash flow growth, combined with a strict discipline around valuations, offers the best way to navigate markets in the months ahead. Despite the last three years being very disappointing for passive EM investors, there has been no shortage of companies performing well. The compelling financial characteristics of our fund give us confidence, that regardless of the direction markets take we can continue to deliver good outcomes.

Discrete performance, 12 months to 31 March
2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Artemis Funds (Lux) – SmartGARP Global Emerging Markets Equity 16.0% -5.3% -3.7% 56.5% -20.8%  - - - - -
MSCI EM (Emerging Markets) NR USD 8.2% -10.7% -11.4% 58.4% -17.7% - - - - -
Past performance is not a guide to the future.
Source: Lipper Limited/Artemis from 31 December 2023 to 31 March 2024 for class I Acc USD
All figures show total returns with dividends and/or income reinvested, net of all charges.
Performance does not take account of any costs incurred when investors buy or sell the fund.
Returns may vary as a result of currency fluctuations if the investor's currency is different to that of the class.
Benchmark: MSCI Emerging Markets Index; the benchmark is a point of reference against which the performance of the fund may be measured. Management of the fund is not restricted by this benchmark. The deviation from the benchmark may be significant and the portfolio of the fund may at times bear little or no resemblance to its benchmark.

Investment in a fund concerns the acquisition of units/shares in the fund and not in the underlying assets of the fund.

Reference to specific shares or companies should not be taken as advice or a recommendation to invest in them.

For information on sustainability-related aspects of a fund, visit the relevant fund page on this website.

For information about Artemis’ fund structures and registration status, visit artemisfunds.com/fund-structures

Any research and analysis in this communication has been obtained by Artemis for its own use. Although this communication is based on sources of information that Artemis believes to be reliable, no guarantee is given as to its accuracy or completeness.

Any statements are based on Artemis’ current opinions and are subject to change without notice. They are not intended to provide investment advice and should not be construed as a recommendation.

Third parties (including FTSE and Morningstar) whose data may be included in this document do not accept any liability for errors or omissions. For information, visit artemisfunds.com/third-party-data.

Important information
The intention of Artemis’ ‘investment insights’ articles is to present objective news, information, data and guidance on finance topics drawn from a diverse collection of sources. Content is not intended to provide tax, legal, insurance or investment advice and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security or investment by Artemis or any third-party. Potential investors should consider the need for independent financial advice. Any research or analysis has been procured by Artemis for its own use and may be acted on in that connection. The contents of articles are based on sources of information believed to be reliable; however, save to the extent required by applicable law or regulations, no guarantee, warranty or representation is given as to its accuracy or completeness. Any forward-looking statements are based on Artemis’ current opinions, expectations and projections. Articles are provided to you only incidentally, and any opinions expressed are subject to change without notice. The source for all data is Artemis, unless stated otherwise. The value of an investment, and any income from it, can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.